In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page.

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...

Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.

HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS – Free Report) in a report published on Monday,Benzinga reports. They currently have a $19.00 price objective on the stock. A ...

Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 million on February 6.

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...

Alumis Inc. and ACELYRIN, INC. have announced their commitment to merge in an all-stock transaction aimed at forming a leading clinical-stage biopharmaceutical company focused on immune-mediated ...

March 08, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and ...

Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – ...